A cellular and molecular basis for the selective desmopressin-induced ACTH release in cushing disease patients: Key role of AVPR1b receptor and potential therapeutic implications

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 10, 2013, Pages 4160-4169

  Luque, R M ^a   Ibanez Costa A ^a   Lopez Sanchez L M ^a   Jimenez Reina L ^a   Venegas Moreno, E ^b   Galvez M A ^c   Villa Osaba, A ^a   Madrazo Atutxa, A M ^b   Japon M A ^b   De La Riva, A ^c   Cano, D A ^b   Benito Lopez P ^c   Soto Moreno, A ^b   Gahete, M D ^a   Leal Cerro, A ^b   Castano J P ^a  

^a UNIVERSITY OF CÓRDOBA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CORTICOTROPIN; DESMOPRESSIN; HYDROCORTISONE; MESSENGER RNA; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1B RECEPTOR;

ACTH SECRETING ADENOMA; ADULT; ARTICLE; CALCIUM MOBILIZATION; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; CORTICOTROPIN TEST; CUSHING DISEASE; DESMOPRESSIN STIMULATION TEST; FEMALE; GENE DOSAGE; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HUMAN TISSUE; HYDROCORTISONE BLOOD LEVEL; HYPOPHYSIS; MAJOR CLINICAL STUDY; MALE; NONFUNCTIONING PITUITARY ADENOMA; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; TUMOR CELL CULTURE; TUMOR GROWTH;

ADENOMA; ADRENOCORTICOTROPIC HORMONE; AGED; DEAMINO ARGININE VASOPRESSIN; HUMANS; MALE; MIDDLE AGED; PITUITARY ACTH HYPERSECRETION; PITUITARY FUNCTION TESTS; PITUITARY GLAND; PITUITARY NEOPLASMS; PROGNOSIS; RECEPTORS, VASOPRESSIN;

EID: 84885215461     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1992     Document Type: Article

References (38)

1. Dworakowska D, Grossman A. The molecular pathogenesis of corticotroph tumours. Eur J Clin Invest. 2012; 42: 665-676.
2. Guaraldi F, Salvatori R. Cushing syndrome: maybe not so uncommon of an endocrine disease. J Am Board Fam Med. 2012; 25: 199-208.
3. Sakai Y, Horiba N, Tozawa F., et al Desmopressin stimulation test for diagnosis of ACTH-dependent Cushing's syndrome. Endocr J. 1997; 44: 687-695.
4. Wang FF, Tang KT, Yen Y.S., et al Plasma corticotrophin response to desmopressin in patients with Cushing's disease correlates with the expression of vasopressin receptor 2, but not with that of vaso-pressin receptor 1 or 3, in their pituitary tumours. Clin Endocrinol (Oxf). 2012; 76: 253-263.
5. Moro M, Putignano P, Losa M., Invitti C, Maraschini C, Cavagnini F. The desmopressin test in the differential diagnosis between Cushing's disease and pseudo-Cushing states. J Clin Endocrinol Metab. 2000; 85: 3569-3574.
6. Losa M, Mortini P, Dylgjeri S., et al Desmopressin stimulation test before and after pituitary surgery in patients with Cushing's disease. Clin Endocrinol. 2001; 55: 61-68.
7. Valéro R., Vallette-Kasic S, Conte-Devolx B, Jaquet P, Brue T. The desmopressin test as a predictive factor of outcome after pituitary surgery for Cushing's disease. Eur J Endocrinol. 2004; 151: 727-733.
8. Castinetti F, Morange I, Dufour H., et al Desmopressin test during petrosal sinus sampling: a valuable tool to discriminate pituitary or ectopic ACTH-dependent Cushing's syndrome. Eur J Endocrinol. 2007; 157: 271-277.
9. Tirabassi G, Faloia E, Papa R., Furlani G, Boscaro M, Arnaldi G. Use of the desmopressintest in the differential diagnosisofpseudo-Cushing state from Cushing's disease. J Clin Endocrinol Metab. 2010; 95: 1115-1122.
10. Tirabassi G, Papa R, Faloia E., Boscaro M, Arnaldi G. Corticotro-phin-releasing hormone and desmopressin tests in the differential diagnosis between Cushing's disease and pseudo-Cushing state: a comparative study. Clin Endocrinol (Oxf). 2011; 75: 666-672.
11. Deipolyi AR, Hirsch JA, Oklu R. Bilateral inferior petrosal sinus sampling with desmopressin [published online ahead of print November 15, 2012]. J Neurointerv Surg. doi:10.1136/neurintsurg-2012-010437.
12. Pecori Giraldi F., Marini E, Torchiana E., Mortini P, Dubini A, Cavagnini F. Corticotrophin-releasing activity of desmopressin in Cushing's disease: lack of correlation between in vivo and in vitro responsiveness. J Endocrinol. 2003; 177: 373-379.
13. Martínez-Fuentes A.J., Moreno-Fernández J, Vázquez-Martínez R, et al. Ghrelin is produced by and directly activates corticotrope cells from adrenocorticotropin-secreting adenomas. J Clin Endocrinol Metab. 2006; 91: 2225-2231.
14. Taboada GF, Luque RM, Bastos W, et al Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol. 2007; 156: 65-74.
15. Neto LV, Machado Ede O, et al Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. J Clin Endocrinol Metab. 2009; 94: 1931-1937.
16. Durán-Prado M., Gahete MD, Martínez-Fuentes AJ, et al. Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. J Clin Endocrinol Metab. 2009; 94: 2634-2643.
17. Luque RM, Gahete MD, Valentine R.J., Kineman RD Examination of the direct effects of metabolic factors on somatotrope function in anon-human primate model, Papio anubis. J Mol Endocrinol. 2006; 37: 25-38.
18. Luque RM, Córdoba-Chacón J, Gahete MD, et al. Kisspeptin regulates gonadotroph and somatotroph function in nonhuman primate pituitary via common and distinct signaling mechanisms. Endocrinology. 2011; 152: 957-966.
19. Durán-Prado M, Gahete MD, Hergueta-Redondo M, et al. The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells. Oncogene. 2012; 31: 2049-2061.
20. René P, de Keyzer Y. The vasopressin receptor of corticotroph pituitary cells. Prog Brain Res. 2002; 139: 345-357.
21. Dahia PL, Ahmed-Shuaib A, Jacobs R.A., et al Vasopressin receptor expression and mutation analysis in corticotropin-secreting tumors. J Clin Endocrinol Metab. 1996; 81: 1768-1771.
22. de Keyzer Y., René P, Lenne F, Auzan C, Clauser E, Bertagna X. V3 vasopressin receptor and corticotropic phenotype in pituitary and nonpituitary tumors. Horm Res. 1997; 47: 259-262.
23. de Keyzer Y., Rene P, Beldjord C., Lenne F, Bertagna X. Overex-pression of vasopressin (V3) and corticotrophin-releasing hormone receptor genes in corticotroph tumours. Clin Endocrinol (Oxf). 1998; 49: 475-482.
24. Abe T, Tachikawa T, Sasaki A., et al Histopathological and physiological characteristics of cultured human ACTH-secreting cells derived from a rapidly growing pituitary adenoma. Brain Tumor Pathol. 2000; 17: 133-138.
25. Stojilkovi SS, Izumi S, Catt KJ Participation of voltage-sensitive calcium channels in pituitary hormone release. J Biol Chem. 1988; 263: 13054-13061.
26. Craighead M, Milne R, Campbell-Wan L, et al. Characterization of a novel and selective V1B receptor antagonist. Prog Brain Res. 2008; 170: 527-535.
27. 1b receptor an-tagonist for the treatment of stress-related disorders. CNS Drug Rev. 2005; 11: 53-68.
28. Ramos AT, Troncone LR, Tufik S. Suppression of adrenocortico-trophic hormone secretion by simultaneous antagonism of vasopressin 1b and CRH-1 receptors on three different stress models. Neuroendocrinology. 2006; 84: 309-316.
29. 1b receptor reduces ACTH, but not corticosterone secretion induced by stress without affecting basal hypothalamic-pituitary-adrenal axis activity. J Endocrinol. 2009; 200: 273-283.
30. Folny V, Raufaste D, Lukovic L., et al Pancreatic vasopressin V1b receptors: characterization in In-R1-G9 cells and localization in humanpancreas. AmJ Physiol Endocrinol Metab. 2003; 285: E566-E576.
31. Luque RM, Park S, Peng X.D., et al Homologous and heterologous in vitro regulation of pig pituitary somatostatin receptor subtypes, sst1, sst2 and sst5 mRNA. J Mol Endocrinol. 2004; 32: 437-448.
32. Córdoba-Chacón J, Gahete MD, Castaño JP, Kineman RD, Luque RM. Homologous and heterologous in vitro regulation of pituitary receptors for somatostatin, growth hormone (GH)-releasing hormone, and ghrelin in a nonhuman primate (Papio anubis). Endocrinology. 2012; 153: 264-272.
33. Rabadan-Diehl C., Lolait SJ, Aguilera G. Regulation of pituitary vasopressin V1b receptor mRNA during stress in the rat. J Neuroendocrinol. 1995; 7: 903-910.
34. Taylor CR, Levenson RM Quantification of immunohistochemistry-issues concerning methods, utility and semiquantitative assessment II. Histopathology. 2006; 49: 411-424.
35. Lolait SJ, Stewart LQ, Jessop D.S., Young WS 3rd, O'Carroll AM. The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors. Endocrinology. 2007; 148: 849-856.
36. René P, Grino M, Viollet C, et al. Overexpression of the V3 vaso-pressin receptor in transgenic mice corticotropes leads to increased basal corticosterone. J Neuroendocrinol. 2002; 14: 737-744.
37. van Wijk P.A., van Neck JW, Rijnberk A, Croughs RJ, Mol JA Proliferation of the murine corticotropic tumour cell line AtT20 is affected by hypophysiotrophic hormones, growth factors and gluco-corticoids. Mol Cell Endocrinol. 1995; 111: 13-19.
38. Koshimizu TA, Nakamura K, Egashira N., Hiroyama M, Nonoguchi H, Tanoue A. Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev. 2012; 92: 1813-1864.